argenx: TED Phase 3 Failure, Vyvgart Growth, And Why I'm Still A Hold (NASDAQ:ARGX)

Core Insights - The analysis focuses on argenx SE's lead product, VYVGART HYTRULO, and a recent safety event related to its use in CIDP patients, indicating that the transition from IVIG to VYVGART HYTRULO may be the primary concern rather than the drug itself [1] Group 1 - The safety event discussed pertains to the transition process for CIDP patients moving from IVIG to VYVGART HYTRULO [1]